Related News
AstraZeneca to invest in China
Print Edition
BRITISH-SWEDISH drugmaker AstraZeneca plans to invest more than US$800 million in China in the next 10 years and strengthen cooperation with local partners, especially in the biologics sector.
AstraZeneca strengthened collaboration between its biologics unit MedImmune and local research organization Wuxi AppTec.
The UK company has an option to acquire WuXi AppTec’s biologics manufacturing capacity in Wuxi with an overall investment valued around US$100 million.
“These initiatives will allow us to connect local untapped pharmaceutical needs with our global portfolio,” said Mark Mallon, executive vice president of International businesses at AstraZeneca.
The drugmaker will also invest US$50 million to expand its development and launch facility on top of its existing manufacturing site in Wuxi to support both local and overseas markets.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
